| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 1 security · passive | ||||||
|
Coherus Oncology, Inc.
13G
CHRS · 19249H103
|
6.5% |
11/4/2025
Event 9/5/2025
|
||||
| Bering Partners II, L.P. ("Bering II") | 4.1% | |||||
| Bering Partners II GP, L.L.C. ("Bering II GP") | 4.1% | |||||
| Bering Partners III, L.P. ("Bering III") | 2.4% | |||||
| Bering Partners III GP, L.L.C. ("Bering III GP") | 2.4% | |||||
| Evgeny Zaytsev ("Zaytsev") | 6.5% | |||||
| Philip Sawyer ("Sawyer") | 6.5% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.